AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17186738 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated bath plus acupoint massage (B-M treatment)
Number of subjects: 82
Study 17186738 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 82
Study 14620892 — intervention group
Group type: EXPERIMENTAL
Intervention: True echogenic intracardiac focus
Number of subjects: 200
Study 14620892 — intervention group
Group type: EXPERIMENTAL
Intervention: False echogenic intracardiac focus
Number of subjects: 200
Study 14620892 — intervention group
Group type: EXPERIMENTAL
Intervention: Specular reflection from the moderator band
Number of subjects: 200
Study 11059521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led asthma training session
Number of subjects: 0
Study 11059521 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 0
Study 8977061 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual laser ablation of the prostate (VLAP)
Number of subjects: 133
Study 8977061 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 133
Study 1629993 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatments for PTSD
Number of subjects: 11
Study 1629993 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral techniques involving direct therapeutic exposure
Number of subjects: 11
Study 1629993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 11
Study 1629993 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 11
Study 1629993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 11
Study 1629993 — intervention group
Group type: COMPARATOR
Intervention: Behavioral techniques
Number of subjects: 11
Study 6512252 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol skin preparation
Number of subjects: 519
Study 6512252 — intervention group
Group type: COMPARATOR
Intervention: 0.5% chlorhexidine in 70% spirit skin preparation
Number of subjects: 519
Study 30225805 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow cortical potential neurofeedback (NF) (n=8)
Number of subjects: 15
Study 30225805 — intervention group
Group type: COMPARATOR
Intervention: EMG biofeedback control training (C) (n=7)
Number of subjects: 15
Study 30225805 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful learners of self-regulation (n=8)
Number of subjects: 15
Study 30225805 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15
Study 30225805 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated participants
Number of subjects: 15
Study 29588862 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive urodynamic testing (IUT)
Number of subjects: 218
Study 29588862 — intervention group
Group type: COMPARATOR
Intervention: no IUT (clinical assessment plus non-invasive tests)
Number of subjects: 218
Study 27466039 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured dietary intervention incorporating portion‐controlled foods
Number of subjects: 40
Study 27466039 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 40
Study 24524375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunchtime Enjoyment Activity and Play (LEAP) intervention
Number of subjects: 275
Study 24524375 — intervention group
Group type: COMPARATOR
Intervention: Control school
Number of subjects: 275
Study 23046499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle advice, monitoring of blood glucose, and further medical treatment for hyperglycaemia as appropriate.
Number of subjects: 682
Study 23046499 — intervention group
Group type: COMPARATOR
Intervention: Routine obstetric care reflecting current clinical practice in Australian hospitals.
Number of subjects: 682
Study 20329570 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone controlled-release (CR) administered orally twice daily for at least 28 days, dosage individualized and up-titrated over the first week.
Number of subjects: 309
Study 20329570 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone controlled-release (CR)
Number of subjects: 309
Study 17587425 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-ciclesonide 400 microg/day
Number of subjects: 319
Study 17587425 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-ciclesonide 800 microg/day
Number of subjects: 319
Study 17587425 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP 800 microg/day
Number of subjects: 319
Study 15584057 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LW group)
Number of subjects: 321
Study 15584057 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight mesh (HW group)
Number of subjects: 321
Study 16845791 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein (100 mg/d)
Number of subjects: 223
Study 16845791 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg/d)
Number of subjects: 223
Study 10962544 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐I b
Number of subjects: 33
Study 10962544 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement drift identified for one rater
Number of subjects: 33
Study 8869110 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In‐DTPA‐Octreotide (octreotide scintigraphy)
Number of subjects: 19
Study 8869110 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 19
Study 1617925 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice daily
Number of subjects: 194
Study 1617925 — intervention group
Group type: COMPARATOR
Intervention: erythromycin 1 g twice daily
Number of subjects: 194
Study 6150717 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine daily for 5 days
Number of subjects: 7
Study 6150717 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg cimetidine daily for 5 days
Number of subjects: 7
Study 6150717 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 30954489 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeno‐associated virus vectored immunoprophylaxis
Number of subjects: 0
Study 29792754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 267
Study 29792754 — intervention group
Group type: COMPARATOR
Intervention: No bevacizumab
Number of subjects: 267
Study 26256769 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including nurse care management, use of a patient registry, academic detailing, and electronic tools
Number of subjects: 53
Study 26256769 — intervention group
Group type: COMPARATOR
Intervention: Electronic tools alone (control condition)
Number of subjects: 53
Study 25358916 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment initiation (pharmacotherapy and/or psychotherapy)
Number of subjects: 1068
Study 25358916 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (pharmacotherapy and psychotherapy)
Number of subjects: 1068
Study 25358916 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy only
Number of subjects: 1068
Study 25358916 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical severity (CGI-ADHD-S score)
Number of subjects: 1068
Study 25358916 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, gender, CGI-ADHD-S score
Number of subjects: 1068
Study 25358916 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental psychological distress, CSI-4 score, bullying involvement
Number of subjects: 1068
Study 23154888 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine oral solution (600 mcg)
Number of subjects: 84
Study 23154888 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine tablets (600 mcg)
Number of subjects: 84
Study 23154888 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine soft gel capsules (600 mcg)
Number of subjects: 84
Study 20054522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group (INT)
Number of subjects: 2033
Study 20054522 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (CON)
Number of subjects: 2033
Study 18612464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight reduction
Number of subjects: 19
Study 18612464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 15814044 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of oral ofloxacin (10 mg/kg/day)
Number of subjects: 235
Study 15814044 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of oral ofloxacin (10 mg/kg/day)
Number of subjects: 235
Study 15814044 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 eligible children infected with Na(R) isolate of S. typhi
Number of subjects: 235
Study 12091805 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 2 (10 microg)
Number of subjects: 24
Study 12091805 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 2 (100 microg)
Number of subjects: 24
Study 12091805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10335727 — intervention group
Group type: COMPARATOR
Intervention: Cooling (forced air at 15 degrees C)
Number of subjects: 9
Study 10335727 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adjust (forced-air warming adjusted to comfort)
Number of subjects: 9
Study 10335727 — intervention group
Group type: COMPARATOR
Intervention: Control (a cotton blanket)
Number of subjects: 9
Study 8606849 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol therapy
Number of subjects: 100
Study 8606849 — intervention group
Group type: COMPARATOR
Intervention: Control group (CF patients not receiving albuterol therapy)
Number of subjects: 100
Study 30672801 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Program (PP)
Number of subjects: 141
Study 30672801 — intervention group
Group type: COMPARATOR
Intervention: No Preventive Program (NPP)
Number of subjects: 141
Study 28862017 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence support
Number of subjects: 643
Study 28862017 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence support and nutritious food supplement
Number of subjects: 643
Study 28862017 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 643
Study 27688102 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab + docetaxel/cisplatin chemotherapy
Number of subjects: 113
Study 27688102 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (docetaxel/cisplatin)
Number of subjects: 113
Study 24754493 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary plaque volume index (PVI) measured by coronary CT angiography
Number of subjects: 224
Study 24754493 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) score determined with the Agatston method
Number of subjects: 224
Study 24754493 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft plaque percentage
Number of subjects: 224
Study 24754493 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancies between CAC score and PVI rank quartiles
Number of subjects: 224
Study 23213986 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion 10 min (Group A, n=25)
Number of subjects: 76
Study 23213986 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion 20 min (Group B, n=25)
Number of subjects: 76
Study 23213986 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion 30 min (Group C, n=26)
Number of subjects: 76
Study 23213986 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 76
Study 19228091 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP plus ABM/P-15
Number of subjects: 28
Study 19228091 — intervention group
Group type: COMPARATOR
Intervention: Autologous PRP
Number of subjects: 28
Study 17455405 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF)
Number of subjects: 30
Study 17455405 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF) plus conventional ultrafiltration (CUF)
Number of subjects: 30
Study 15678730 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine with fentanyl 2 microg mL(-1) at 10 mL h(-1) (Group R1, n = 38)
Number of subjects: 80
Study 15678730 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine with fentanyl 2 microg mL(-1) at 8 mL h(-1) (Group R2, n = 39)
Number of subjects: 80
Study 11770217 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic assessment of treatments for lung cancer
Number of subjects: 0
Study 9640992 — intervention group
Group type: COMPARATOR
Intervention: High-dose alprazolam
Number of subjects: 0
Study 9640992 — intervention group
Group type: COMPARATOR
Intervention: Low-dose alprazolam
Number of subjects: 0
Study 9640992 — intervention group
Group type: COMPARATOR
Intervention: Chronic treatment with high-dose alprazolam
Number of subjects: 0
Study 9640992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9640992 — intervention group
Group type: COMPARATOR
Intervention: Chronic treatment with lorazepam
Number of subjects: 0
Study 9640992 — intervention group
Group type: COMPARATOR
Intervention: Single high and low doses of alprazolam and lorazepam
Number of subjects: 0
Study 8136599 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine solution
Number of subjects: 150
Study 8136599 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine plus normal saline solution
Number of subjects: 150
Study 8136599 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine plus sodium bicarbonate solution
Number of subjects: 150
Study 2685688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (3 mg/m2 i.v.) and Mitoxantrone (10 mg/m2 i.v.) every 3 weeks x 3 and every 4 weeks thereafter (VM)
Number of subjects: 230
Study 2685688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (3 mg/m2 i.v.) and Epirubicin (40 mg/m2 i.v.) every 3 weeks x 3 and every 4 weeks thereafter (VE)
Number of subjects: 230
Study 806018 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 per cent amino acids
Number of subjects: 20
Study 806018 — intervention group
Group type: COMPARATOR
Intervention: 5 per cent dextrose
Number of subjects: 20
Study 31307636 — intervention group
Group type: EXPERIMENTAL
Intervention: 320-row area-detector CT (ADCT)
Number of subjects: 12
Study 31307636 — intervention group
Group type: COMPARATOR
Intervention: 16-row multi-detector CT (MDCT)
Number of subjects: 12
Study 28406648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (n = 119)
Number of subjects: 237
Study 28406648 — intervention group
Group type: COMPARATOR
Intervention: Dynamic therapy (n = 118)
Number of subjects: 237
Study 26098588 — intervention group
Group type: EXPERIMENTAL
Intervention: Social resilience training
Number of subjects: 48
Study 26098588 — intervention group
Group type: COMPARATOR
Intervention: Cultural awareness training
Number of subjects: 48
Study 23715669 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid administration (41 patients)
Number of subjects: 413
Study 23715669 — intervention group
Group type: COMPARATOR
Intervention: No colloid administration (82 patients)
Number of subjects: 413
Study 23715669 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fluid balance
Number of subjects: 413
Study 23715669 — intervention group
Group type: COMPARATOR
Intervention: Negative fluid balance
Number of subjects: 413
Study 23715669 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid administration
Number of subjects: 413
Study 20576266 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 40
Study 20576266 — intervention group
Group type: COMPARATOR
Intervention: Control (no hormonal contraception)
Number of subjects: 40
Study 19223438 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to venlafaxine
Number of subjects: 334
Study 19223438 — intervention group
Group type: COMPARATOR
Intervention: Switch to another SSRI
Number of subjects: 334
Study 19223438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (adjunctive)
Number of subjects: 334
Study 19223438 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (adjunctive, N=10)
Number of subjects: 334
Study 16512804 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (1.2 x 10^9 CFU Lactobacillus rhamnosus Lcr35 plus prebiotic preparation)
Number of subjects: 39
Study 16512804 — intervention group
Group type: COMPARATOR
Intervention: Prebiotics alone (identically appearing prebiotic preparation)
Number of subjects: 39
Study 16512804 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Synbiotics vs Prebiotics
Number of subjects: 39
Study 12972220 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month intervention
Number of subjects: 386
Study 10752330 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 change from 1.0 to 0.21, then returned to 1.0 (Group 1)
Number of subjects: 40
Study 10752330 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 change from 0.8 to 0.4 (Group 2)
Number of subjects: 40
Study 10752330 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 change from 1.0 to 0.21 with blood sampling every two minutes (Group 3)
Number of subjects: 40
Study 10752330 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 change from 0.8 to 0.4 with blood sampling every two minutes (Group 4)
Number of subjects: 40
Study 8966047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoergic inflammatory response
Number of subjects: 0
Study 8966047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperergic inflammatory reaction
Number of subjects: 0
Study 1571645 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational facilitator approach
Number of subjects: 264
Study 1571645 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer courier approach
Number of subjects: 264
Study 1571645 — intervention group
Group type: COMPARATOR
Intervention: Postal delivery approach
Number of subjects: 264
Study 3838152 — intervention group
Group type: COMPARATOR
Intervention: Atropine (1 mg)
Number of subjects: 10
Study 3838152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (10 mg)
Number of subjects: 10
Study 3838152 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 29789904 — intervention group
Group type: EXPERIMENTAL
Intervention: Link Endo-Model
Number of subjects: 51
Study 29789904 — intervention group
Group type: COMPARATOR
Intervention: EnduRo
Number of subjects: 51
Study 27345663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 114
Study 27345663 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional neck exercises
Number of subjects: 114
Study 27345663 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 114
Study 27345663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi and Conventional neck exercises
Number of subjects: 114
Study 25516022 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist Medical and Mental Health Unit
Number of subjects: 600
Study 25516022 — intervention group
Group type: COMPARATOR
Intervention: Standard geriatric or internal medical wards
Number of subjects: 600
Study 22762855 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic rosuvastatin 40 mg tablet (Zentiva)
Number of subjects: 42
Study 22762855 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Crestor)
Number of subjects: 42
Study 22762855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (Generic and Reference)
Number of subjects: 42
Study 20347483 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis
Number of subjects: 3179
Study 17921912 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg qd
Number of subjects: 1484
Study 17921912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1484
Study 15893095 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroid prevention program
Number of subjects: 3207
Study 15893095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 3207
Study 12789994 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Simply White Clear Whitening Gel (18% carbamide peroxide), applied for 30 minutes, twice daily, for 3 weeks.
Number of subjects: 80
Study 12789994 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (control group).
Number of subjects: 80
Study 9585288 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of midazolam plus 75 microg of fentanyl
Number of subjects: 30
Study 9585288 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of saline
Number of subjects: 30
Study 7661944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 33
Study 7661944 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 33
Study 7661944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound salvage after failed landmark attempts
Number of subjects: 33
Study 2554716 — intervention group
Group type: EXPERIMENTAL
Intervention: Danpro-S (0.8 g.kg‐1.d‐1)
Number of subjects: 17
Study 2554716 — intervention group
Group type: EXPERIMENTAL
Intervention: Danprotex-H 40 (0.8 g.kg‐1.d‐1)
Number of subjects: 17
Study 489192 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 15.100 (20 mg, single oral dose, administered 60 min prior to allergen inhalation)
Number of subjects: 10
Study 489192 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 15.000 (10 mg)
Number of subjects: 10
Study 489192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 489192 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated controls
Number of subjects: 10
Study 31904693 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive reminder system intervention
Number of subjects: 174
Study 31904693 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study 31904693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 174
Study 29777048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal clear corneal incision (CCI)
Number of subjects: 100
Study 29777048 — intervention group
Group type: COMPARATOR
Intervention: Temporal clear corneal incision (CCI)
Number of subjects: 100
Study 29641737 — intervention group
Group type: EXPERIMENTAL
Intervention: One time high dose 300,000 IU of ergocalciferol (VD2)
Number of subjects: 20